MassDevice

Edwards shares superior long-term outcomes from TAVR studies

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...
The New England Journal of Medicine

Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
TipRanks on MSN

Edwards Lifesciences’ New Study on Valve Sizing Algorithm: A Potential Game Changer?

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

Corcym, CardioPrecision set sights on robotic heart valve replacement

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...
Investing.com South Africa

Edwards Lifesciences stock rises after SAPIEN 3 TAVR shows long-term benefits

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Edwards Lifesciences: Inflection Incoming, But When?

Edwards Lifesciences remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and ...
Nasdaq

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...